Further evidence for the long-term safety of guselkumab

Br J Dermatol. 2023 Jul 7;189(1):10-11. doi: 10.1093/bjd/ljad161.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Humans
  • Psoriasis* / drug therapy

Substances

  • guselkumab
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal